Cross-talk between Chk1 and Chk2 in double-mutant thymocytes

被引:48
|
作者
Zaugg, Kathrin
Su, Yu-Wen
Reilly, Patrick T.
Moolani, Yasmin
Cheung, Carol C.
Hakem, Razquallah
Hirao, Atsushi
Elledge, Stephen J.
Mak, Tak W.
机构
[1] Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada
[2] Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada
[3] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada
[4] Univ Hlth Network, Toronto, ON M5G 2C1, Canada
[5] Univ Toronto, Inst Med Sci, MARS Ctr, Toronto, ON M5G 2C1, Canada
[6] Ontario Canc Inst, Toronto, ON M5G 2C1, Canada
[7] Keio Univ, Sch Med, Sakaguchi Lab Dev Biol, Shinjuku, Tokyo 1608582, Japan
[8] Harvard Univ, Brigham & Womens Hosp, Ctr Genet & Genom, Howard Hughes Med Inst,Dept Genet, Boston, MA 02115 USA
关键词
apoptosis; cancer; T cells; p53; bcl2;
D O I
10.1073/pnas.0611584104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Chk1 is a checkpoint kinase and an important regulator of mammalian cell division. Because null mutation of Chk1 in mice is embryonic lethal, we used the Cre-loxP system and the Lck promoter to generate conditional mutant mice in which Chk1 was deleted only in the T lineage. In the absence of Chk1, the transition of CD4(-)CD8(-) double-negative (DN) thymocytes to CD4(+)CD8(+) double-positive (DP) cells was blocked due to an increase in apoptosis at the DN2 and DN3 stages. Strikingly, loss of Chk1 activated the checkpoint kinase Chk2 as well as the tumor suppressor p53 in these thymocytes. However, the developmental defects caused by Chk1 deletion were not rescued by p53 inactivation. Significantly, even though Chk1 deletion is highly lethal in proliferating tissues, we succeeded in using in vivo methods to generate Chk1/Chk2 double-knockout T cells. Analysis of these T cells revealed an interesting interaction between Chk1 and Chk2 functions that partially rescued the apoptosis of the double-mutant cells. Thus, Chk1 is both critical for the survival of proliferating cells and engages in cross-talk with the Chk2 checkpoint kinase pathway. These factors have implications for the targeting of Chk1 as an anticancer therapy.
引用
收藏
页码:3805 / 3810
页数:6
相关论文
共 50 条
  • [31] Correlation between Molecular Docking and the Stabilizing Interaction of HOMO-LUMO: Spirostans in CHK1 and CHK2, an In Silico Cancer Approach
    Rosales-Lopez, Antonio
    Lopez-Castillo, Guiee N.
    Sandoval-Ramirez, Jesus
    Teran, Joel L.
    Carrasco-Carballo, Alan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [32] 下调Chk1和Chk2基因促进射线照射后HeLa细胞凋亡
    高庆蕾
    叶飞
    邢辉谢
    大兴
    卢运萍
    周剑锋
    马丁
    中华肿瘤杂志, 2009, (03)
  • [33] Chk1/chk2在Aβ致伤海马神经元中的表达及意义
    黄昕艳
    尉荣翠
    杨智
    李壮
    刘爽
    黑龙江医药科学, 2015, 38 (01) : 72 - 73
  • [34] 人脑胶质瘤中ATM、ATR、Chk1和Chk2基因表达研究
    周雪梅
    乔健
    王娆
    黄建萍
    王慧博
    邱裕友
    陈永珍
    中华神经医学杂志, 2009, (07) : 653 - 657
  • [35] 细胞周期检测点激酶CHK1、CHK2与放射敏感性
    王玉祥
    祝淑钗
    肿瘤学杂志, 2007, (03) : 178 - 181
  • [36] In vitro and in vivo potentiation of cytotoxic therapy by XL844, an orally bioavailable inhibitor of Chk1 and Chk2
    Matthews, David J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3504S - 3505S
  • [37] Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation
    Ye, F.
    Yang, Z.
    Liu, Y.
    Gong, D.
    Ji, T.
    Wang, J.
    Xi, B.
    Zhou, J.
    Ma, D.
    Gao, Q.
    CANCER GENE THERAPY, 2014, 21 (05) : 209 - 217
  • [38] Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines
    Papp, Thilo
    Niemetz, Annett
    Dosdahl, Nils
    Kumar, Krishan
    Schiffmann, Dietmar
    ONCOLOGY REPORTS, 2007, 17 (01) : 135 - 140
  • [39] Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response
    Stracker, Travis H.
    Usui, Takehiko
    Petrini, John H. J.
    DNA REPAIR, 2009, 8 (09) : 1047 - 1054
  • [40] The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
    E M Bahassi
    J L Ovesen
    A L Riesenberg
    W Z Bernstein
    P E Hasty
    P J Stambrook
    Oncogene, 2008, 27 : 3977 - 3985